US · Healthcare · Biotechnology
EPS came in at 0.59 against a street estimate of 0.56 — a beat of 5.4%.
Analysts rate Innoviva Inc a buy (4 buy, 0 hold, 1 sell out of 5) with an average price target of $35.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.99% |
| Dimensional Fund Advisors, Inc. | 6.22% |
| Vanguard Portfolio Management, LLC | 5.84% |
| Renaissance Technologies Corp | 5.59% |
| State Street Corp | 4.52% |
| Vanguard Capital Management, LLC | 4.37% |
| Millennium Management LLC | 3.52% |
| Geode Capital Management, LLC | 2.87% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 INNOVIVA, INC. – 10-Q SUMMARY (JUNE 30, 2026) HEADLINE NUMBERS • Total Revenue (6 months): $217.6 million vs. $188.9 million prior year (+15.2%) - | 2026-08-05 |
| Results announced · Q3 2026 INNOVIVA Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $119.6 million, up 19% year-over-year from $100.3 million in Q2 2025 • | 2026-08-05 |
| Board / officer change · Q2 2026 INNOVIVA, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Two board members resigned on May 12, 2026: Derek Small (CEO of Syndeio BioSciences Inc | 2026-05-18 |
| Quarterly report · Q1 2026 INNOVIVA, INC. — 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Q1 2026 Net Income: $186.6 million (vs. Q1 2025 net loss of $46.6 million) • Q1 2026 Net | 2026-05-06 |
| Results announced · Q2 2026 INNOVIVA, INC. – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenue: $98.0 million, up 11% from $88.6 million in Q1 2025 • Royalty revenue ( | 2026-05-06 |
| Shareholder vote results · Q2 2026 INNOVIVA, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held May 4, 2026 • Total shares voted: approximately 66 million (56.7m fo | 2026-05-04 |
| Proxy statement · Q1 2026 INNOVIVA, INC. – 2026 ANNUAL MEETING PROXY SUMMARY --- CEO COMPENSATION • Pavel Raifeld (CEO) total compensation: Not disclosed in this document ex | 2026-03-24 |
| Annual report FY2025 INNOVIVA, INC. – 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Company market capitalization: $1.26 billion (as of June 30, 2025) • Outstanding shares: | 2026-02-25 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Innoviva Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.